期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 28, 期 3, 页码 369-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2019.02.008
关键词
CTLA-4; Immune checkpoint; Melanoma; Non-small cell lung carcinoma; PD-1; PD-L1; Renal cell carcinoma; Urothelial carcinoma
资金
- National Institutes of Health [T32 CA009599]
Immunotherapy has led to unprecedented improvement in the treatment and prognosis of high-risk resectable and metastatic disease across cancer types. Nowhere is this better highlighted than in the management of advanced and metastatic melanoma with the introduction of molecularly targeted therapies and immune checkpoint inhibitors. Following their success in melanoma, immunotherapies have also been evaluated and their use approved in the management across a variety of other solid malignancies in the neoadjuvant, adjuvant, and advanced/metastatic setting. This review provides an overview of the current landscape of immune checkpoint inhibition for solid malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据